IPCA Laboratories has announced its financial results for the fourth quarter, showing moderate year-on-year growth across key indicators. The company reported a net profit of ₹68 crore, compared to ₹59.6 crore in the same quarter last year, marking a 14.1% increase.
Revenue for the quarter stood at ₹2,247 crore, reflecting a 10.5% rise from ₹2,033 crore in the corresponding period of the previous year. The company’s earnings before interest, taxes, depreciation, and amortization (EBITDA) also improved, reaching ₹429 crore, up from ₹322 crore a year ago. This represents an increase of 33.3%.
The EBITDA margin expanded to 19.09%, compared to 15.83% in the same quarter last year, indicating improved operational efficiency.
In the meantime, IPCA Laboratories shares opened at ₹1,503.00, and, at the time of writing, reached a high of ₹1,514.00 and a low of ₹1,466.00 during the trading session. The stock remains below its 52-week high of ₹1,755.90 but well above its 52-week low of ₹1,052.00.
